Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMND NASDAQ:HOTH NASDAQ:SYBX NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$1.03-3.7%$1.02$0.80▼$2.18$5.85M0.99136,513 shs170,349 shsHOTHHoth Therapeutics$1.44+3.6%$1.51$0.66▼$3.80$18.43M0.671.01 million shs4.00 million shsSYBXSynlogic$1.78+2.9%$1.59$0.90▼$1.96$20.24M0.5529,099 shs122,223 shsTRAWTraws Pharma$2.98-2.9%$1.98$0.97▼$19.44$21.88M1.69254,582 shs100,241 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine-3.74%+8.34%-13.45%-8.85%-33.12%HOTHHoth Therapeutics+3.60%-6.49%-20.00%+5.88%+63.64%SYBXSynlogic+2.89%+4.09%0.00%+11.25%+23.61%TRAWTraws Pharma-2.93%+1.02%+46.80%+76.33%-39.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$1.03-3.7%$1.02$0.80▼$2.18$5.85M0.99136,513 shs170,349 shsHOTHHoth Therapeutics$1.44+3.6%$1.51$0.66▼$3.80$18.43M0.671.01 million shs4.00 million shsSYBXSynlogic$1.78+2.9%$1.59$0.90▼$1.96$20.24M0.5529,099 shs122,223 shsTRAWTraws Pharma$2.98-2.9%$1.98$0.97▼$19.44$21.88M1.69254,582 shs100,241 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine-3.74%+8.34%-13.45%-8.85%-33.12%HOTHHoth Therapeutics+3.60%-6.49%-20.00%+5.88%+63.64%SYBXSynlogic+2.89%+4.09%0.00%+11.25%+23.61%TRAWTraws Pharma-2.93%+1.02%+46.80%+76.33%-39.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMNDClearmind Medicine 0.00N/AN/AN/AHOTHHoth Therapeutics 2.33Hold$4.50212.50% UpsideSYBXSynlogic 1.00SellN/AN/ATRAWTraws Pharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CMND, TRAW, SYBX, and HOTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025HOTHHoth TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SYBXSynlogicWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025TRAWTraws PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025HOTHHoth TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SYBXSynlogicWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TRAWTraws PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/18/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/30/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/23/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/ASYBXSynlogicN/AN/AN/AN/A$1.09 per shareN/ATRAWTraws Pharma$2.90M7.32N/AN/A($8.66) per share-0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMNDClearmind Medicine-$5.26M-$0.76N/A∞N/AN/A-173.87%-70.55%N/AHOTHHoth Therapeutics-$8.19M-$1.07N/AN/AN/AN/A-114.32%-105.92%11/11/2025 (Estimated)SYBXSynlogic-$23.36M-$0.08N/AN/AN/AN/A-8.09%-5.50%11/11/2025 (Estimated)TRAWTraws Pharma-$166.52M$88.830.03N/AN/A3,028.25%-1,812.48%512.72%11/13/2025 (Estimated)Latest CMND, TRAW, SYBX, and HOTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025SYBXSynlogic-$0.11N/AN/AN/AN/AN/A9/11/2025Q3 2025CMNDClearmind MedicineN/A-$0.25N/A-$0.25N/AN/A8/14/2025Q2 2025TRAWTraws Pharma-$8.75-$0.11+$8.64-$0.11$0.06 million$2.73 million8/12/2025Q2 2025HOTHHoth Therapeutics-$0.27-$0.17+$0.10-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMNDClearmind MedicineN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ASYBXSynlogicN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMNDClearmind MedicineN/A1.321.32HOTHHoth TherapeuticsN/A27.5427.54SYBXSynlogicN/A3.633.63TRAWTraws PharmaN/A2.092.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMNDClearmind Medicine96.05%HOTHHoth Therapeutics7.08%SYBXSynlogic63.40%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipCMNDClearmind MedicineN/AHOTHHoth Therapeutics6.92%SYBXSynlogic3.02%TRAWTraws Pharma14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMNDClearmind MedicineN/A5.47 millionN/ANot OptionableHOTHHoth Therapeutics413.26 million12.34 millionNot OptionableSYBXSynlogic8011.70 million11.35 millionOptionableTRAWTraws Pharma177.13 million6.13 millionOptionableCMND, TRAW, SYBX, and HOTH HeadlinesRecent News About These CompaniesTraws Pharma begins patient dosing in phase 2 study of ratutrelvir, a ritonavir-free anti-viral treatment in newly diagnosed CovidOctober 16, 2025 | pharmabiz.comPTraws Pharma doses first patient with ratutrelvir in Phase 2 COVID studiesOctober 14, 2025 | msn.comTraws Pharma Begins Phase 2 COVID-19 Treatment StudyOctober 14, 2025 | msn.comTraws Pharma Initiates Phase 2 Trials for Ratutrelvir, a Ritonavir-Free COVID-19 Treatment, Aiming for Non-Inferiority to PAXLOVID®October 14, 2025 | quiverquant.comQTraws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025October 14, 2025 | globenewswire.comTraws Pharma Appoints Dr. John Leaman to Board, Confirms CEO and CFO RolesOctober 12, 2025 | msn.comTraws Pharma appoints John Leaman as independent directorOctober 6, 2025 | msn.comTraws Pharma, Inc. Appoints John Leaman, MD, to Board of Directors and Officially Names Key Executives as CEO and CFOOctober 6, 2025 | quiverquant.comQTraws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key ExecutivesOctober 6, 2025 | finance.yahoo.comAnnovis Bio appoints CFOSeptember 25, 2025 | msn.comTraws Pharma Completes Acquisition of Virom AssetsSeptember 12, 2025 | tipranks.comTraws Pharma Earnings Call: Optimism Amid ChallengesAugust 31, 2025 | tipranks.comTraws Pharma receives approval to proceed with Phase 2 COVID studiesAugust 18, 2025 | msn.comTraws Pharma, Inc.: Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025August 18, 2025 | finanznachrichten.deTraws Pharma Gains Approval for Phase 2 COVID-19 TrialsAugust 18, 2025 | msn.comTraws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025August 18, 2025 | globenewswire.comTraws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral ProgramsAugust 16, 2025 | msn.comTraws Pharma Advances Antiviral Programs Amid Revenue GrowthAugust 16, 2025 | theglobeandmail.comTraws Pharma, Inc. (NASDAQ:TRAW) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | insidermonkey.comTraws Pharma, Inc.: Traws Pharma Reports Second Quarter 2025 Results and Business HighlightsAugust 14, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMND, TRAW, SYBX, and HOTH Company DescriptionsClearmind Medicine NASDAQ:CMND$1.03 -0.04 (-3.74%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.03 0.00 (0.00%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Hoth Therapeutics NASDAQ:HOTH$1.44 +0.05 (+3.60%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.38 -0.06 (-4.51%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Synlogic NASDAQ:SYBX$1.78 +0.05 (+2.89%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.73 -0.05 (-2.81%) As of 10/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.Traws Pharma NASDAQ:TRAW$2.98 -0.09 (-2.93%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$2.98 0.00 (-0.17%) As of 10/21/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
